Search Results - "Sack, Françoise N'Go"

Favorable Impact of Post-ASCT Consolidative Immunotherapy with RITUXIMAB, rINF-a2b and rIL2 on Overall Survival and Progression-Free Survival in Advanced Stage or Relapsed/Refractory Follicular Lymphoma: Results of a Phase II Study by Eveillard, Jean-Richard, Ianotto, Jean-Christophe, Tempescul, Adrian, Guillerm, Gaelle, Dalbiès, Florence, Saad, Hussam, Calloc'h, Ronan LE, Dagorn, Anaïg, Sack, Françoise N’go, Berthou, Christian

“…Abstract 3066 Advanced stage III/IV or relapsed/refractory follicular lymphoma (FL) can hardly be cured with conventional chemotherapy and patients, even after…”
Get full text

Appraisal of IgM Kappa/IgM Lambda Variations Using HevyLite® After Rituximab As Consolidation Therapy in Patients with Waldenström's Macroglobulinemia by Eveillard, Jean-Richard, Achour, Achouak, Sack, Françoise N'Go, Tempescul, Adrian, Calloc'h, Ronan LE, Dagorne, Anaïg, Pietrantuono, Annie, Chauvet, Daniel, Bendaoud, Boutahar, Berthou, Christian, Hillion, Sophie, Renaudineau, Yves

“…Abstract 4879…”
Get full text

Appraisal of IgM Kappa/IgM Lambda Variations Using HevyLite® After Rituximab As Consolidation Therapy in Patients with Waldenström’s Macroglobulinemia by Eveillard, Jean-Richard, Achour, Achouak, Sack, Françoise N’Go, Tempescul, Adrian, Calloc'h, Ronan LE, Dagorne, Anaïg, Pietrantuono, Annie, Chauvet, Daniel, Bendaoud, Boutahar, Berthou, Christian, Hillion, Sophie, Renaudineau, Yves

“…Abstract 4879 In Waldenström’s Macroglobulinemia (WM), response rates to rituximab (RTX) range from 30% to 75%. RTX is also known to generate a transient IgM…”
Get full text